If you have been reading about ghrelin receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-27. Numbers and descriptions here follow the published literature rather than marketing material.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
== History == Benorterone was developed in the late 1950s, was first reported to possess antiandrogenic activity in 1964, and was investigated in clinical trials in the mid-to-late 1960s. It was the first known antiandrogen to be studied in humans. The drug was found to be effective in the treatment of acne, seborrhea, and hirsutism in women. In addition, unlike progestogenic antiandrogens such as cyproterone acetate, it seldom produced side effects in women and did not affect menstruation. However, in males, benorterone was not effective for acne, and produced high rates of gynecomastia (in 12 out of 13 or 92% of young men treated with 75 to 300 mg/day benorterone). Shortly following the observance of this side effect, it was withdrawn from clinical studies. Subsequently, cyproterone acetate, which has a greatly reduced risk of gynecomastia by virtue of its concomitant progestogenic and antigonadotropic actions (which results in suppression of estrogen levels), was developed instead and was introduced for medical use in 1973. In addition, spironolactone, a steroidal antimineralocorticoid that was introduced for medical use in 1959, was discovered to possess potent antiandrogenic activity in 1969, and became widely used clinically as an antiandrogen after its first use in an androgen-dependent condition in 1978.
=== 1973 === c. 20 April: Lynda Gough (19). The first sexually motivated killing the Wests are known to have committed together. Gough was a lodger at 25 Cromwell Street and shared sex partners with Rose. Following her disappearance, Gough's mother travelled to Cromwell Street to enquire about her daughter's whereabouts and saw Rose wearing her daughter's clothes and slippers. She was informed that Lynda had moved to find work in Weston-super-Mare. Lynda's remains were buried in an inspection pit beneath the garage, which was later converted into a bathroom. 10 November: Carol Ann Cooper (15). Cooper had been placed into care following her mother's death in 1966. She was last seen alive by her boyfriend in the suburb of Warndon boarding a bus to her grandmother's home. Fred referred to Cooper as "Scar Hand" in reference to a recent firework burn she had sustained. Cooper was the final victim unearthed from the cellar. Her skull was bound with surgical tape and her dismembered limbs bound with cord and braiding cloth. 27 December: Lucy Partington (21). Partington was an Exeter University student and the cousin of novelist Martin Amis. She was abducted from a bus stop along the A435. Her precise date of death may have been one week after her disappearance, as Fred admitted himself into the casualty unit of Gloucestershire Royal Hospital with a serious laceration of his right hand on 3 January, possibly sustained as he dismembered Partington's body. Her body was discovered in the Cromwell Street cellar on 6 March 1994.
Conservation strategies include the maintenance of: 1) refuge plants and reservoir hosts to preserve the EcM fungal community after harvesting; 2) mature trees to provide seedlings with a diverse array of EcM fungi; and 3) old-growth stands that have diverse macro- and microhabitats and support varied EcM fungal communities. Preservation of natural forest floor constituents and retention of woody debris and substrates may also be important. In one study concerning Douglas-fir seedlings, removal of forest floor debris and soil compaction decreased EcM fungal diversity and abundance by 60%. Removal of pinegrass similarly reduced the diversity and richness of EcM fungi. Some strategies, such as prescribed burns, have different effects on different types of EcM communities, ranging from negative to neutral or positive. Large ex situ culture collections of fungi, including ectomycorrhizal fungi, are maintained throughout the world as insurance against genetic loss. However, these collections are incomplete.
Sources: en.wikipedia.org
== History == The term "food drunk" has sometimes been used to describe the supposed state of a person after overeating. In October 1905, Thomas Edison (then 58 years old) declared that "the country is food drunk.... the people eat too much and sleep too much, and don't work enough". The phrase was echoed by Dr J E Rullfson of Toledo after fasting for sixty days from January 5, 1907. He held that the entire human race is food drunk, saying "the dinner eaten by Napoleon just before the Battle of Leipzig proved so indigestible that the monarch's brain was clouded and as a result the battle was lost and a pie which King Philip failed to digest caused the revolt of the Netherlands."
=== Production === Except for the small numbers assembled or produced in Australia, all Mustangs were built by North American initially at Inglewood, California, but then additionally in Dallas, Texas.
== Analysis == Ligation may also serve as a DNA analysis method. Some techniques employ rolling circle amplification. The most notable of these is described by Smolina et al., 2007 & Smolina et al., 2008 using fluorescence in situ hybridization and peptide nucleic acids. They developed and employed this technique for analyses of bacterial chromosomes.
Sources: en.wikipedia.org
== See also == Comparative endocrinology Endocrine disease Hormone Hormone replacement therapy Neuroendocrinology Pediatric endocrinology Reproductive endocrinology and infertility Wildlife endocrinology List of instruments used in endocrinology
Aquileia is a comune (municipality) in the Friuli-Venezia Giulia region of northeastern Italy. It is situated at the head of the Adriatic at the edge of the lagoons, about 10 kilometres (6 mi) from the sea, on the river Natiso (modern Natisone), the course of which has changed somewhat since the Roman era. In classical antiquity, Aquileia was a major Roman city with an estimated population close to 100,000 in the 2nd century AD. Founded as a Roman military colony in 181 BC, Aquileia became the capital of the Augustan X region and a metropolitan center for early Christianity. During late antiquity, it was the first city in the Italian Peninsula to be sacked by Attila the Hun. Today, Aquileia is one of the most significant archaeological sites in northern Italy. Its ruins, including mosaics and an early Christian basilica, are a UNESCO World Heritage Site. Aquileia also holds historical importance as one of the former capitals of Friuli, with its coat of arms being the symbol of the region.
=== Ethidium bromide === Ethidium bromide intercalates and stains DNA, providing a fluorescent red-orange stain. Although it will not stain healthy cells, it can be used to identify cells that are in the final stages of apoptosis – such cells have much more permeable membranes. Consequently, ethidium bromide is often used as a marker for apoptosis in cells populations and to locate bands of DNA in gel electrophoresis. The stain may also be used in conjunction with acridine orange (AO) in viable cell counting. This EB/AO combined stain causes live cells to fluoresce green whilst apoptotic cells retain the distinctive red-orange fluorescence.
=== Endocrine === Dexamethasone is the treatment for the very rare disorder of glucocorticoid resistance. In adrenal insufficiency and Addison's disease, dexamethasone is prescribed when the patient does not respond well to prednisone or methylprednisolone. It can be used in congenital adrenal hyperplasia in older adolescents and adults to suppress adrenocorticotropic hormone (ACTH) production. It is typically given at night.
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
Reversed-phase liquid chromatography is standard for purity, and mass spectrometry is standard for identity. Amino acid analysis is used when quantitative composition matters. No single technique answers every question, so laboratories usually combine two or three.